| http://purl.uniprot.org/citations/16879301 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/16879301 | http://www.w3.org/2000/01/rdf-schema#comment | "MBP8298 is a synthetic peptide with a sequence corresponding to amino acid residues 82-98 of human myelin basic protein (DENPVVHFFKNIVTPRT). It represents the immunodominant target for both B cells and T cells in multiple sclerosis (MS) patients with HLA haplotype DR2. Its administration in accordance with the principle of high dose tolerance results in long-term suppression of anti-myelin basic protein (MBP) autoantibody levels in the cerebrospinal fluid (CSF) of a large fraction of progressive MS patients. MBP8298 was evaluated in a 24-month placebo-controlled double-blinded Phase II clinical trial in 32 patients with progressive MS. The objective was to assess the clinical efficacy of 500 mg of MBP8298 administered intravenously every 6 months, as measured by changes in Expanded Disability Status Scale (EDSS) scores. Contingency analysis for all patients at 24 months showed no significant difference between MBP8298 and placebo-treatments (n = 32, P = 0.29). Contingency analysis in an HLA Class II defined subgroup showed a statistically significant benefit of MBP8298 treatment compared with placebo in patients with HLA haplotypes DR2 and/or DR4 (n = 20, P = 0.01). Long-term follow-up treatment and assessment of patients in this responder group showed a median time to progression of 78 months for MBP8298 treated patients compared with 18 months for placebo-treatment (Kaplan-Meier analysis, P = 0.004; relative rate of progression = 0.23). Anti-MBP autoantibody levels in the CSF of most MBP8298 treated patients were suppressed, but antibody suppression was not predictive of clinical benefit. Anti-MBP autoantibodies that reappeared in the CSF of one patient at 36 months, whilst under treatment with MBP8298, were not reactive with the MBP8298 peptide in vitro. The identification of a responder subgroup (62.5% of the patients in this study) enables a more efficient design of a large confirmatory clinical trial of MBP8298. The probability that patients with other less common HLA-DR haplotypes will respond to this treatment should not be ignored."xsd:string |
| http://purl.uniprot.org/citations/16879301 | http://purl.org/dc/terms/identifier | "doi:10.1111/j.1468-1331.2006.01533.x"xsd:string |
| http://purl.uniprot.org/citations/16879301 | http://purl.uniprot.org/core/author | "Krantz M.J."xsd:string |
| http://purl.uniprot.org/citations/16879301 | http://purl.uniprot.org/core/author | "Warren K.G."xsd:string |
| http://purl.uniprot.org/citations/16879301 | http://purl.uniprot.org/core/author | "Catz I."xsd:string |
| http://purl.uniprot.org/citations/16879301 | http://purl.uniprot.org/core/author | "Ferenczi L.Z."xsd:string |
| http://purl.uniprot.org/citations/16879301 | http://purl.uniprot.org/core/date | "2006"xsd:gYear |
| http://purl.uniprot.org/citations/16879301 | http://purl.uniprot.org/core/name | "Eur J Neurol"xsd:string |
| http://purl.uniprot.org/citations/16879301 | http://purl.uniprot.org/core/pages | "887-895"xsd:string |
| http://purl.uniprot.org/citations/16879301 | http://purl.uniprot.org/core/title | "Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment."xsd:string |
| http://purl.uniprot.org/citations/16879301 | http://purl.uniprot.org/core/volume | "13"xsd:string |
| http://purl.uniprot.org/citations/16879301 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/16879301 |
| http://purl.uniprot.org/citations/16879301 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/16879301 |
| http://purl.uniprot.org/uniprot/#_A0A0A7C3H3-mappedCitation-16879301 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/16879301 |
| http://purl.uniprot.org/uniprot/#_A0A0A7C3I1-mappedCitation-16879301 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/16879301 |
| http://purl.uniprot.org/uniprot/#_A0A0A7C3I5-mappedCitation-16879301 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/16879301 |
| http://purl.uniprot.org/uniprot/#_A0A0A0WDZ3-mappedCitation-16879301 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/16879301 |
| http://purl.uniprot.org/uniprot/#_A0A0E3DD60-mappedCitation-16879301 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/16879301 |
| http://purl.uniprot.org/uniprot/#_A0A0E3DD66-mappedCitation-16879301 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/16879301 |
| http://purl.uniprot.org/uniprot/#_A0A141AZI1-mappedCitation-16879301 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/16879301 |
| http://purl.uniprot.org/uniprot/#_A0A141AZI3-mappedCitation-16879301 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/16879301 |
| http://purl.uniprot.org/uniprot/#_A0A141AZI4-mappedCitation-16879301 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/16879301 |
| http://purl.uniprot.org/uniprot/#_A0A0A0WAE5-mappedCitation-16879301 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/16879301 |
| http://purl.uniprot.org/uniprot/#_A0A0A0WB88-mappedCitation-16879301 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/16879301 |